Subject: License Agreement between the University of Michigan and OncoFusion Therapeutics, Inc.

Action Requested: Approval of the License Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Technology Transfer while reviewing the technology transfer agreement that then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by this Board and agreed to by the parties involved in this plan.

This proposed license agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professors Shaomeng Wang, Gilbert Omenn, and Arul Chinnaiyan are employees of the University of Michigan ("University") and partial owners of OncoFusion Therapeutics, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Shaomeng Wang, PhD, a Professor in the Department of Internal Medicine – Hematology/Oncology, Gilbert Omenn, MD, PhD, a Professor in the Department of Computational Medicine and Bioinformatics, and Arul Chinnaiyan, MD, PhD, a Professor in the Department of Pathology, are partial owners of a for-profit company called OncoFusion Therapeutics, Inc. (the "Company"). The Company was formed to develop and commercialize small molecules for the treatment of cancer and other diseases and desires to license from the University of Michigan the University’s rights associated with the following technology:

UM OTT File No. 7378, entitled: “Fused 1,4-Diazepines as BET Bromodomain Inhibitors” (Inventors: Shaomeng Wang, Fuming Xu and Jiantao Hu)

The Office of Technology Transfer selected the Company as a University partner and negotiated the terms of the proposed Agreement in accordance with University policy and its accepted licensing principles.

Parties to the Agreement:

The Regents of the University of Michigan and OncoFusion Therapeutics, Inc.
Agreement Terms Include:

Agreement terms include granting the Company an exclusive license with the right to grant sublicenses. The Company will pay a royalty on sales and reimburse patent costs. The University may receive additional equity in the Company, along with the right to purchase more equity.

The University will retain ownership of the licensed technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Pecuniary Interest:

The pecuniary interests of Drs. Wang, Omenn, and Chinnaiyan arise from their ownership interests in OncoFusion Therapeutics, Inc.

Net Effect:

The Office of Technology Transfer has negotiated and finalized the terms of a worldwide exclusive license agreement for patents related to UM OTT File No. 7378 for the fields of use of treating and of diagnosing human diseases. OncoFusion Therapeutics, Inc. will obtain use and commercialization rights to the above listed University technology.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the Agreement between the University and OncoFusion Therapeutics, Inc.

Respectfully submitted,

S. Jack Hu
Vice President for Research

March 2018